A New Scan to Guide Liver Cancer Treatment
Novel PET Imaging to Guide Therapy in Hepatocellular Carcinoma
This project aims to find a faster way to see if liver cancer treatments are working by using a special type of scan.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11142654 on NIH RePORTER |
What this research studies
Liver cancer, specifically hepatocellular carcinoma (HCC), is a serious condition often treated with targeted radiation called Yttrium-90 (Y90) radioembolization. Currently, it takes months to know if this treatment is successful using standard scans like MRI or CT, causing uncertainty for patients and doctors. This research explores a new kind of scan, called 18F-FSPG PET, which might show treatment response much sooner. This special scan works by detecting a specific activity in cancer cells that is linked to how they respond to radiation. By getting earlier information, doctors can make quicker decisions about the next steps in your care.
Who could benefit from this research
Good fit: Patients with hepatocellular carcinoma (HCC) who are undergoing or considering Yttrium-90 (Y90) radioembolization treatment might be ideal candidates.
Not a fit: Patients with other types of cancer or those not receiving Yttrium-90 radioembolization for liver cancer may not directly benefit from this specific imaging approach.
Why it matters
Potential benefit: If successful, this new scanning method could help doctors quickly understand if a liver cancer treatment is working, allowing for faster adjustments to care plans.
How similar studies have performed: Researchers have previously used 18F-FSPG PET in liver cancer for detection and response evaluation, suggesting a foundation for this innovative approach.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Manning, Henry Charles — University of Tx Md Anderson Can Ctr
- Study coordinator: Manning, Henry Charles
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.